康辰药业：KC1086片临床试验申请正式获得FDA许可

Core Viewpoint - The company has received FDA approval for the clinical trial of its drug KC1086, which is a novel small molecule inhibitor designed for the treatment of advanced recurrent or metastatic solid tumors [1] Group 1 - The FDA issued a "Study May Proceed" notification, allowing the clinical trial application for KC1086 to move forward [1] - KC1086 is developed entirely by Beijing Kangchen Pharmaceutical Co., Ltd. and targets lysine acetyltransferase 6 with high selectivity and efficacy [1] - The drug is intended for use in treating advanced recurrent or metastatic solid tumors [1]